Arrowhead Research Corporation announced signing of new pharma deals with Merck, through a subsidiary, to undertake an evaluation of a novel proprietary therapeutic monoclonal antibody candidate derived from Arrowhead’s human-derived peptide targeting and discovery program.
Merck will bear the costs involved in evaluating the candidate as detailed in the signing of this pharma deals.
Arrowhead’s target discovery and delivery platform consists of a large library of unique human-derived peptide sequences selected for their ability to bind cell surface targets and rapidly internalize within cells of more than 30 distinct tissues and multiple tumor types.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Related reports: Antibody Partnering Terms and Agreements
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity